Digitalni repozitorij raziskovalnih organizacij Slovenije

Iskanje po repozitoriju
A+ | A- | Pomoč | SLO | ENG

Iskalni niz: išči po
išči po
išči po
išči po

Možnosti:
  Ponastavi


Iskalni niz: "avtor" (Erik Brecelj) .

1 - 10 / 29
Na začetekNa prejšnjo stran123Na naslednjo stranNa konec
1.
2.
3.
Ultrasonographic changes in the liver tumors as indicators of adequate tumor coverage with electric field for effective electrochemotherapy
Nina Boc, Ibrahim Edhemović, Bor Kos, Maja Marolt-Mušič, Erik Brecelj, Blaž Trotovšek, Maša Omerzel, Mihajlo Djokić, Damijan Miklavčič, Maja Čemažar, Gregor Serša, 2018, izvirni znanstveni članek

Povzetek: The aim of the study was to characterize ultrasonographic (US) findings during and after electrochemotherapy of liver tumors to determine the actual ablation zone and to verify the coverage of the treated tumor with a sufficiently strong electric field for effective electrochemotherapy. Patients and methods. US findings from two representative patients that describe immediate and delayed tumor changes after electrochemotherapy of colorectal liver metastases are presented. Results. The US findings were interrelated with magnetic resonance imaging (MRI). Electrochemotherapy-treated tumors were exposed to electric pulses based on computational treatment planning. The US findings indicate immediate appearance of hyperechogenic microbubbles along the electrode tracks. Within minutes, the tumors became evenly hyperechogenic, and simultaneously, an oedematous rim was formed presenting as a hypoechogenic formation which persisted for several hours after treatment. The US findings overlapped with computed electric field distribution in the treated tissue, indicating adequate coverage of tumors with sufficiently strong electric field, which may predict an effective treatment outcome. Conclusions. US provides a tool for assessment of appropriate electrode insertion for intraoperative electrochemotherapy of liver tumors and assessment of the appropriate coverage of a tumor with a sufficiently strong electric field and can serve as predictor of the response of tumors.
Ključne besede: elctrochemotherapy, ultrasound, treatment plan, liver
Objavljeno v DiRROS: 11.06.2024; Ogledov: 80; Prenosov: 38
.pdf Celotno besedilo (1,07 MB)

4.
Induction chemotherapy, chemoradiotherapy and consolidation chemotherapy in preoperative treatment of rectal cancer : long-term results of phase II OIGIT-01 Trial
Danijela Golo, Jasna But-Hadžić, Franc Anderluh, Erik Brecelj, Ibrahim Edhemović, Ana Jeromen, Mirko Omejc, Irena Oblak, Ajra Šečerov Ermenc, Vaneja Velenik, 2018, izvirni znanstveni članek

Povzetek: The purpose of the study was to improve treatment efficacy for locally advanced rectal cancer (LARC) by shifting half of adjuvant chemotherapy preoperatively to one induction and two consolidation cycles. Patients and methods Between October 2011 and April 2013, 66 patients with LARC were treated with one induction chemotherapy cycle followed by chemoradiotherapy (CRT), two consolidation cycles, surgery and three adjuvant capecitabine cycles. Radiation doses were 50.4 Gy for T2-3 and 54 Gy for T4 tumours in 1.8 Gy daily fraction. The doses of concomitant and neo/adjuvant capecitabine were 825 mg/m2/12h and 1250mg/m2/12h, respectively. The primary endpoint was pathologic complete response (pCR). Results Forty-three (65.1%) patients were treated according to protocol. The compliance rates for induction, consolidation, and adjuvant chemotherapy were 98.5%, 93.8% and 87.3%, respectively. CRT was completed by 65/66 patients, with G % 3 non-hematologic toxicity at 13.6%. The rate of pCR (17.5%) was not increased, but N and the total-down staging rates were 77.7% and 79.3%, respectively. In a median follow-up of 55 months, we recorded one local relapse (LR) (1.6%). The 5-year disease-free survival (DFS) and overall survival (OS) rates were 64.0% (95% CI 63.89%64.11) and 69.5% (95% CI 69.39%69.61), respectively. Conclusions In LARC preoperative treatment intensification with capecitabine before and after radiotherapy is well tolerated, with a high compliance rate and acceptable toxicity. Though it does not improve the local effect, it achieves a high LR rate, DFS, and OS.
Ključne besede: rectal cancer, neoadjuvant chemotherapy, preoperative chemoradiotherapy
Objavljeno v DiRROS: 11.06.2024; Ogledov: 74; Prenosov: 49
.pdf Celotno besedilo (1,27 MB)
Gradivo ima več datotek! Več...

5.
Mesenteric ischemia after capecitabine treatment in rectal cancer and resultant short bowel syndrome is not an absolute contraindication for radical oncological treatment
Ana Perpar, Erik Brecelj, Nada Rotovnik-Kozjek, Franc Anderluh, Irena Oblak, Marija Skoblar Vidmar, Vaneja Velenik, 2015, drugi znanstveni članki

Povzetek: Thrombotic events, arterial or venous in origin, still remain a source of substantial morbidity and mortality in cancer patients. The propensity for their development in oncology patients is partially a consequence of the disease itself and partially a result of our attempts to treat it. One of the rarest and deadliest thromboembolic complications is arterial mesenteric ischemia. The high mortality rate is caused by its rarity and by its non-specific clinical presentation, both of which make early diagnosis and treatment difficult. Hence, most diagnoses and treatments occur late in the course of the disease. The issue survivors of arterial mesenteric ischemia may face is short bowel syndrome, which has become a chronic condition after the introduction of parenteral nutrition at home. We present a 73-year-old rectal cancer patient who developed acute arterial mesenteric thrombosis at the beginning of the pre-operative radiochemotherapy. Almost the entire length of his small intestine, except for the proximal 50 cm of it, and the ascending colon had to be resected. After multiorgan failure his condition improved, and he was able to successfully complete radical treatment (preoperative radiotherapy and surgery) for the rectal carcinoma, despite developing short bowel syndrome (SBS) and being dependent upon home-based parenteral nutrition to fully cover his nutritional needs. Mesenteric ischemia and resultant short bowel syndrome are not absolute contraindications for radical oncological treatment since such patients can still achieve long-term remission.
Ključne besede: acute mesenteric ischemia, capecitabine, multiorgan failure, rectal cancer, short bowel syndrome
Objavljeno v DiRROS: 23.04.2024; Ogledov: 198; Prenosov: 56
.pdf Celotno besedilo (557,53 KB)

6.
Phase II study of fluorouracil, leucovorin and interferon alpha-2a in patients with advanced colon cancer
Borut Štabuc, Aleksandra Markovič, Erik Brecelj, Samir Bešlija, Tomaž-Edvard Cizej, 1998, izvirni znanstveni članek

Povzetek: Based on in viro studies that have demonstrated synergy between fluorouracil (5-FU) and leucovorin (LV) as well as between 5-FU and recombinant alpha-2a interferon (IFN) against colon cancer cell lines a phase II study was carried out to evaluate the toxicity and clinical activity of 5-FU modulated with LV and IFN in patients with metastatic colon cancer. Twenty-two chemotherapy naive patients with measurable metastases of colon cancer have been treated with daily doses of 5-FU 600 mg/m2 in 6-hr intravenous infusion, and of LV 20 mg/m2 intravenously and IFN 6 MU subcutaneously, for 5 days every 4 weeks. Median age was 60 years, median PS (ECOG) was 1 (range 0-2). Liver, soft tissue and lung metastases were found in 12, 5 and 8 patients, respectively. Nineteen patients had a single metastatic site, two double, whereas one had more than two metastatic sites. Patients had 2-9 (mean 5) cycles of treatment.Objective response was observed in 7 patients (32%), and stable disease in 7 patients (32%). Overall median survival was 12.5 months, and for responders 14.4 months. Responses were generally short and median time for progression was 5.5 months. The most frequent adverse reactions were flu-like syndrome (50%), nausea/vomiting (36%), diarhoea (13Č), stomatitis (27%) and leucopenia (13%). This regimen of 5-FU with LV and IFN administration does notappear to be superior to previously published shedules of 5-FU with IFN or 5-FU with LV.
Objavljeno v DiRROS: 19.01.2024; Ogledov: 289; Prenosov: 88
.pdf Celotno besedilo (430,62 KB)

7.
Sodobno zdravljenje lokalno napredovalega in recidivnega raka danke
Erik Brecelj, 2022, objavljeni znanstveni prispevek na konferenci

Povzetek: Zdravljenje lokalno napredovalega in recidivnega raka danke je zahtevno. Z uvedbo boljše diagnostike, novih načinov predoperativnega zdravljenja na eni strani in z bolj agresivno kirurško terapijo na drugi strani dosegamo več R0 resekcij, ki edine omogočajo potencialno ozdravitev. Še vedno pa so ti posegi za bolnike neredko mutilantni. Z ustreznimi tehnikami rekonstrukcije dosegamo večjo možnost resektabilnosti, hkrati pa so posledice kirurškega zdravljenja manjše. Pomembna pri vrnitvi bolnika v normalno življenje sta prehranska podpora in rehabilitacija. Tako kompleksno zdravljenje je možno samo v multidisciplinarnem timu.
Ključne besede: rak danke, kirurško zdravljenje, rak prebavil
Objavljeno v DiRROS: 13.01.2023; Ogledov: 687; Prenosov: 143
.pdf Celotno besedilo (88,46 KB)

8.
9.
10.
Priročnik za bolnike z izločalno stomo
Andreja Klinc, Dragica Tomc, Sabina Medjedović, 2021, slovar, enciklopedija, leksikon, priročnik, atlas, zemljevid

Ključne besede: rak črevesja, rak sečil, stoma
Objavljeno v DiRROS: 14.07.2022; Ogledov: 759; Prenosov: 244
.pdf Celotno besedilo (769,40 KB)

Iskanje izvedeno v 0.65 sek.
Na vrh